RE:On GLP-1 agonists US Senate passes anti-patent thicket billSuch action will impact and preclude certain biologics like antibody-drug conjugates (ADC) and engineered vaccines / viruses from adding varius payloads or seperate transgenes to their original patented products, all in an effort to expand their product's effectiveness or expand their market share / product lifecycle through strategies like "product hopping" or "evergreening".
Consequently the recently passed Inflation Reduction Act (IRA) passed into law in 2022, gives biologics 13 years of market exclusivity from the date of approval, is added fuel to accelerate Big Pharma's need to acquire late stage platform companies like ONCY, which has a platform drug in pelareorep that can be used in the treatment of multiple cancers. in combination with other immunotherapy agents such as PD-L1 immune checkpoint inhibitors, bispecifics, ADCs, CAR-T therapy, and small moleclues like CDK4/6 and PARP inhibitors, for example.